In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

In a paper published in MedComm, an international team of scientists provided an overview of the advancements in the ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.